An announcement from SciSparc Ltd. ( (SPRC) ) is now available.
On April 25, 2025, SciSparc Ltd. announced a collaboration with Clearmind Medicine Inc. that resulted in the filing of an international patent application for a novel treatment targeting anorexia, bulimia, and other eating disorders. This development leverages the combination of 3-Methylmethcathinone and SciSparc’s Palmitoylethanolamide, aiming to address complex factors associated with eating disorders. The announcement highlights the potential impact on the treatment landscape for these serious mental health conditions, which affect millions globally and have seen a significant rise in prevalence.
More about SciSparc Ltd.
SciSparc Ltd. is a specialty clinical-stage pharmaceutical company focusing on the development of therapies for central nervous system disorders. The company is engaged in drug development programs based on cannabinoid pharmaceuticals, including treatments for Tourette Syndrome, Alzheimer’s disease, and autism spectrum disorder. SciSparc also has a subsidiary selling hemp seed oil-based products.
YTD Price Performance: -25.38%
Average Trading Volume: 2,303,924
Technical Sentiment Signal: Buy
Current Market Cap: $3.16M
See more insights into SPRC stock on TipRanks’ Stock Analysis page.